Halozyme Therapeutics (HALO) Assets Average (2011 - 2026)

Halozyme Therapeutics (HALO) has 16 years of Assets Average data on file, last reported at $2.6 billion in Q1 2026.

• On a quarterly basis, Assets Average rose 22.02% year-over-year to $2.6 billion in Q1 2026; TTM through Mar 2026 was $2.6 billion, a 22.02% increase from a year earlier, with the FY2025 full-year figure at $2.3 billion, up 20.86% from the prior year.
• Assets Average for Q1 2026 stood at $2.6 billion, up from $2.4 billion in the prior quarter.
• Over the last five years, Assets Average for HALO reached as high as $2.6 billion in Q1 2026 and fell as low as $1.1 billion in Q1 2022.
• Historically, Assets Average has averaged $1.9 billion across 5 years, with a median of $1.9 billion in 2022.
• Across the five-year window, Assets Average soared 64.88% in 2022 and decreased 2.16% in 2023, its largest moves.
• Year by year, Assets Average stood at $1.9 billion in 2022, then declined by 2.16% to $1.8 billion in 2023, then increased by 15.32% to $2.1 billion in 2024, then increased by 13.51% to $2.4 billion in 2025, then increased by 9.51% to $2.6 billion in 2026.
• Per Business Quant data, the three most recent Assets Average figures were $2.6 billion in Q1 2026, $2.4 billion in Q4 2025, and $2.1 billion in Q3 2025.